Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclatasvir + Peg-Interferon Alfa-2a + Ribavirin in HCV Genotype 1
NCT01389323Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2011
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of daclatasvir in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Primary endpoint: Sustained Virologic Response at Post-treatment Week 12. Started Sep 2011; status: completed.
02
Drugs
daclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01389323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01389323.